BACKGROUND: The fifth leading cause of cancer deaths among women is ovarian cancer (OC), which originates primarily in the ovarian surface epithelium (OSE) that surrounds the ovary. Permanent removal of the OSE could provide a novel strategy to substantially reduce OC risk, while retaining the benefits of ovarian function, including gameto- and steroidogenesis. It must be determined whether ovarian surface epitheliectomy (OSEx) carries deleterious side effects, including loss of menstrual cyclicity, infertility or scarring (e.g. adhesions), prior to any clinical application of this strategy. To achieve this, we selected the non-human primate, rhesus macaque, for long-term (12 month) studies on the effects of OSEx. METHODS: Rhesus macaque females underwent OSEx by detergent treatment and were then monitored for menstrual cyclicity (menstruation, steroidogenesis and follicle development) and adverse side effects (tissue scarring or adhesions). Ovaries were collected at 6 or 12 months and examined for evidence of tissue damage, follicle rupture and regression of the corpus luteum. The ovarian surface was examined immunohistologically for signs of epithelial replacement, using markers for OSE and fimbrial epithelium (FE), a possible alternative source of pelvic tumors diagnosed as OC. RESULTS: After OSEx, menstrual cycle length, estrogen and progesterone production, follicle rupture and luteal regression appeared normal. No evidence of adhesions was seen. At 6 and 12 months post-OSEx, the ovarian surface was sparsely populated by cells expressing OSE and FE markers. Proliferative activity in this population was notably low. CONCLUSIONS: OSEx may provide a novel method to reduce the risk of OC, without sacrificing ovarian function, although the effects on fertility remain to be tested. The absence of epithelial replacement via enhanced proliferation suggests OSEx does not increase malignant potential. Complete and permanent OSEx may be feasible.
BACKGROUND: The fifth leading cause of cancer deaths among women is ovarian cancer (OC), which originates primarily in the ovarian surface epithelium (OSE) that surrounds the ovary. Permanent removal of the OSE could provide a novel strategy to substantially reduce OC risk, while retaining the benefits of ovarian function, including gameto- and steroidogenesis. It must be determined whether ovarian surface epitheliectomy (OSEx) carries deleterious side effects, including loss of menstrual cyclicity, infertility or scarring (e.g. adhesions), prior to any clinical application of this strategy. To achieve this, we selected the non-human primate, rhesus macaque, for long-term (12 month) studies on the effects of OSEx. METHODS:Rhesus macaque females underwent OSEx by detergent treatment and were then monitored for menstrual cyclicity (menstruation, steroidogenesis and follicle development) and adverse side effects (tissue scarring or adhesions). Ovaries were collected at 6 or 12 months and examined for evidence of tissue damage, follicle rupture and regression of the corpus luteum. The ovarian surface was examined immunohistologically for signs of epithelial replacement, using markers for OSE and fimbrial epithelium (FE), a possible alternative source of pelvic tumors diagnosed as OC. RESULTS: After OSEx, menstrual cycle length, estrogen and progesterone production, follicle rupture and luteal regression appeared normal. No evidence of adhesions was seen. At 6 and 12 months post-OSEx, the ovarian surface was sparsely populated by cells expressing OSE and FE markers. Proliferative activity in this population was notably low. CONCLUSIONS:OSEx may provide a novel method to reduce the risk of OC, without sacrificing ovarian function, although the effects on fertility remain to be tested. The absence of epithelial replacement via enhanced proliferation suggests OSEx does not increase malignant potential. Complete and permanent OSEx may be feasible.
Authors: David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum Journal: Am J Surg Pathol Date: 2007-02 Impact factor: 6.394
Authors: Fabiola Medeiros; Michael G Muto; Yonghee Lee; Julia A Elvin; Michael J Callahan; Colleen Feltmate; Judy E Garber; Daniel W Cramer; Christopher P Crum Journal: Am J Surg Pathol Date: 2006-02 Impact factor: 6.394
Authors: Rebecca T Marquez; Keith A Baggerly; Andrea P Patterson; Jinsong Liu; Russell Broaddus; Michael Frumovitz; Edward N Atkinson; David I Smith; Lynn Hartmann; David Fishman; Andrew Berchuck; Regina Whitaker; David M Gershenson; Gordon B Mills; Robert C Bast; Karen H Lu Journal: Clin Cancer Res Date: 2005-09-01 Impact factor: 12.531
Authors: Tanja Pejovic; Jane E Yates; Hong Y Liu; Laura E Hays; Yassmine Akkari; Yumi Torimaru; Winifred Keeble; R Keaney Rathbun; William H Rodgers; Allen E Bale; Najim Ameziane; C Michael Zwaan; Abdellatif Errami; Philippe Thuillier; Fabio Cappuccini; Susan B Olson; Joanna M Cain; Grover C Bagby Journal: Cancer Res Date: 2006-09-15 Impact factor: 12.701
Authors: Ov Daniel Slayden; Francis Kathryn E Friason; Kise Rosen Bond; Emily Cathleen Mishler Journal: J Med Primatol Date: 2018-07-04 Impact factor: 0.667
Authors: Błażej Chermuła; Wiesława Kranc; Piotr Celichowski; Bogusława Stelmach; Hanna Piotrowska-Kempisty; Paul Mozdziak; Leszek Pawelczyk; Robert Zygmunt Spaczyński; Bartosz Kempisty Journal: J Clin Med Date: 2021-12-24 Impact factor: 4.241